banner
 
bar

program

slides
bar
 
 

Best Practice Guidelines for Insulin Use in Type 2 Diabetes

WebCAST

pre-program survey
We Invite You to Take a Moment and Complete This Pre-Program
Knowledge and Clinical Performance Survey.
Thank You

Webcast CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Program Medium

Internet-based program

Method of Physician Participation Utilized in Learning Process

There are no fees for participating and receiving CME credit for this activity. During the period July 6, 2012 through July 6, 2014 participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity, and are expected to view all nine segments totaling 3 hours and 25 minutes to successfully complete the activity and earn CME credit; 3) register and complete the evaluation form and post-test; 4) score 100% on the post-test; and 5) print out your CME certificate.

Estimated Time to Complete Educational Activity

3.0 hours

Course Overview

In this web-based program, physicians will learn how recent advances in basic and clinical research have helped to advance the understanding of treatment advances in type 2 diabetes.

Release Date

July 6, 2012

Expiration Date

July 6, 2014

Intended Audience

This program is intended for all primary care, internal medicine, and endocrinology specialists, as well as other healthcare providers caring for patients with diabetes.

Registration

Enrollment for this WebCAST is complimentary, and clinicians are invited to participate in this CME-certified WebCAST and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support

logoThis CME activity is supported by an educational grant from sanofi-aventis U.S. Inc., A SANOFI COMPANY

Physician Continuing Education

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Massachusetts Medical School, Office of CME and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The University of Massachusetts Medical School designates this enduring material for a maximum of 3.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity, and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials

Program Faculty and Disclosure

CHARLES F. SHAEFER Jr, MD, FACP
(Program Chairman)

Assistant Clinical Professor of Medicine
Medical College of Georgia
University Health Systems
Augusta, GA

Consultant: Sanofi-Aventis, BMS-AZ
Speaker's Bureau: Sanofi-Aventis, Amylin, BI/Lilly, BMS-AZ, Novartis



GEORGE DAILEY, MD

Clinical Professor of Medicine
University of California San Diego
Senior Consultant in Diabetes & Endocrinology
Scripps Clinic & Scripps Whittier Diabetes Institute
La Jolla, CA

Consultant: Sanofi-Aventis, Merck, Amylin
Speaker's Bureau: Merck, Sanofi-Aventis, BMS-Astra Zeneca, Lilly-
Boerhinger Ingelheim, Amylin
Investigator: Sanofi-Aventis, GlaxoSmithKline, Merck, Eli Lilly,
Amylin, Novo-Nordisk, Roche, Novartis, Halozyme,
Lexicon, BMS-AZ, Gilead, ITCA, Minimed



LAWRENCE BLONDE, MD, FACP, FACE
Director, Ochsner Diabetes Clinical Research Unit
Department of Endocrinology, Diabetes and Metabolic Diseases
Ochsner Medical Center
New Orleans, LA

Consultant: Amylin Pharmaceuticals, Inc., Gilead, GlaxoSmithKline,
JNJ-Janssen, Merck & Co., Novo Nordisk, Sanofi-Aventis,
Santarus
Speaker's Bureau: Amylin Pharmaceuticals, Inc., Boehringer Ingelheim
Pharmaceuticals, Merck & Co., Johnson & Johnson
Diabetes Institute, LLC., Novo Nordisk, Santarus
Investigator: Eli Lilly and Co., Novo Nordisk and Sanofi-Aventis



MELANIE MABREY, DNP, RN, ACNP, BC-ADM

Clinical Associate-
Duke University School of Medicine and Duke University School of Nursing
Director, Inpatient Endocrinology/Diabetes Nurse Practitioner Program
Durham Regional Hospital, Duke University Health System
Durham, NC

Consultant: sanofi-aventis
Speaker's Bureau: sanofi-aventis

Program Managers and Web Editor Disclosure

Program Manager Gideon Bosker, MD has nothing to disclose.

Program Reviewer Denise Leary has nothing to disclose.

Educational Objectives

Upon completion of this educational activity, participants should:

  1. Have a better understanding of the epidemiology and prevalence of T2D and the unique needs, barriers to optimal care, and management strategies for these patients to ensure national (ADA, AACE) target goals are achieved with appropriate pharmacologic—insulin and/or OADs—interventions
  2. Be better able to assess the need their diabetic patients have for insulin therapy in the internal medicine setting; and specifically, be better able to navigate the clinical decision tree to determine the need for early insulin use and intensification of insulin therapy in patients who are not achieving target goals on one or more OADs
  3. Become more proficient at achieving ADA and AACE target goals; and, to compare insulin formulations—and account for pharmacokinetic considerations—to determine the optimal alignment with patient types and clinical profiles
  4. Gain a better understanding of the safety and efficacy of different insulin-based therapies for achieving ADA, ACP, and AACE glycemic and HA1c target goals in T2DM; and, what clinical situations are best suited to initiating and/or intensifying therapy with insulin-based interventions
  5. Be more skilled at engaging patients in discussions about why, when, and how to initiate insulin-based therapy for diabetes; and communicating the advantages, strategies for compliance, regimen adherence, education, and ease of self-administration for insulin-based treatments

Hardware and Software Requirements:

To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to printout the CME certificate.

Privacy Policy

When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:

  • We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.
  • For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
  • We may use the Information to send you information about other CME activities that CMEducation Resources is offering.
  • If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.
  • You should check this privacy policy periodically to see whether we have made any changes.

Disclaimer

Copyright © 2012 by Pharmatecture, LLC and CMEducation Resources, LLC All rights reserved.

Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.

Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.

Opinions expressed herein are not necessarily those of Pharmatecture, LLC, CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

pre-program survey
We Invite You to Take a Moment and Complete This Pre-Program
Knowledge and Clinical Performance Survey.
Thank You

bar

program

slides
bar

I have read this CME information statement and wish to participate in this CME activity.

Copyright © CMEducation Resources, LLC and Pharmatecture, LLC

 
6

 

Key Program Topics Include:

b-Cell
A1c
AACE
AACE/ACE
ACCORD
ADA
ADA/EASD
ADVANCE
Basal Insulin
biguanides
DCCT
Diabetes

DPP-4 inhibitor
Dyslipidemia
ESRD
Exenatide
FPG
Glargine
glimiperide
GLP agonist
Glucose
glyburide
Glycemia
Glycemic
HbA1c

HDL
Hypertension
Hypoglycemia
incretin
Insulin
Insulin detemir
insulinopenia
LDL
metformin
Microalbumin
NHANES
NPH
Obesity

Type 2
PPG
prandial
PREMIX
Sulfonylureas
T2D
T2DM
Thiazolidinedione
troglitazone
TZD
UKPDS
VADT